首页> 外文期刊>European journal of vascular and endovascular surgery: the official journal of the European Society for Vascular Surgery >Ultrasound guided human thrombin injection. A new modality in the management of femoral artery pseudo-aneurysms.
【24h】

Ultrasound guided human thrombin injection. A new modality in the management of femoral artery pseudo-aneurysms.

机译:超声引导人凝血酶注射。股动脉假性动脉瘤的治疗新模式。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES: We report our initial results of a prospective study of duplex ultrasound-guided injection (UGTI ) of thrombin in the management of femoral artery pseudo-aneurysms. We used human thrombin to avoid the increase in the human antibodies directed against fibrinogen, with the use of bovine thrombus, that preclude further utilisation of the bovine fibrin glue during cardio-thoracic surgery. METHODS: From 1999 to 2001, 19 patients, aged 69 (range 52-85) years presented with 21 femoral pseudo-aneurysms were treated. The mean pseudoaneurysm diameter was 30 (15-55) mm. All but two were secondary to cardiac procedures and the common femoral artery was the injured vessel in all instances. Patients were referred within 2-21 days following their iatrogenic injury. RESULTS: Immediate thrombosis of the sac occurred in 19 (90%) of the 21 pseudo-aneurysms. After a second injection, complete occlusion occurred in the remaining two patients. Two patients (CI 95%; 1-19) with three femoral pseudo-aneurysms developed leg pain. Duplex ultrasound follow-up showed two recurrences (9.5% - CI 95%; 1-19) and both were treated by repeat UGTI. There was no conversion to surgical repair. CONCLUSION: This percutaneous minimally invasive technique is safe and effective in the management of iatrogenic pseudo-aneurysms in this high-risk group of patients. Human thrombin has significant advantages over bovine thrombin. Copyright 2001 Harcourt Publishers Limited.
机译:目的:我们报告了凝血酶双链超声引导注射(UGTI)在股动脉假性动脉瘤治疗中的前瞻性研究的初步结果。我们使用人凝血酶通过使用牛血栓来避免针对纤维蛋白原的人抗体的增加,从而阻止了在心胸外科手术期间进一步利用牛纤维蛋白胶。方法:1999年至2001年,共收治19例年龄在69岁(范围52-85岁)的21例股骨假性动脉瘤。假性动脉瘤的平均直径为30(15-55)mm。除两名外,其余所有患者均接受了心脏手术,在所有情况下股总动脉是受伤的血管。医源性损伤后2-21天内将患者转诊。结果:21个假性动脉瘤中有19个(90%)发生了囊的立即血栓形成。第二次注射后,其余两名患者完全闭塞。两名患有三个股骨假性动脉瘤的患者(CI 95%; 1-19)发展为腿痛。双重超声随访显示两次复发(9.5%-CI 95%; 1-19),均通过重复UGTI治疗。没有转换为手术修复。结论:这种经皮微创技术在治疗高危患者中医源性假性动脉瘤是安全有效的。人凝血酶比牛凝血酶具有明显的优势。版权所有2001 Harcourt Publishers Limited。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号